Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer
- 15 November 2018
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 19 (12) , 1-14
Abstract
Opinion statement Use of poly(ADP-ribose) polymerase (PARP) inhibitors has greatly increased over the past 5 years. With several new Food and Drug Administration (FDA) approvals, three PARP inhibitors have entered into standard of care treatment for epithelial ovarian cancer (including ovarian, fallopian tube, and primary peritoneal cancer). Olaparib and rucaparib currently have indications for treatment of recurrent BRCA mutant ovarian cancer. Olaparib, rucaparib, and niraparib all have indications for maintenance therapy in recurrent platinum-sensitive ovarian cancer after response to platinum-based therapy. In our practice, we use both olaparib and rucaparib in the recurrent setting, and all three PARP inhibitors in the maintenance setting. Choice of which PARP inhibitor to use in either setting is largely based upon baseline laboratory values, number of prior therapies, and presence of a BRCA mutation and/or homologous recombination deficiency (HRD). As (HRD) and other biomarker assessments continue to improve, we anticipate being able to better identify which patients might most benefit from PARP inhibitor therapy in the future. The clinically available PARP inhibitors are currently undergoing extensive investigations in clinical trials. Other newer agents such as talazoparib, veliparib, 2X-121, and CEP-9722 are in earlier stages of development. As more FDA-approved indications for PARP inhibitor therapy in ovarian cancer become available, we anticipate the decision of which PARP inhibitor to use will become increasingly complex.Keywords
Funding Information
- National Institutes of Health (5 T32 CA101642 02, 2P50 CA109298)
- University of Texas MD Anderson Cancer Center (P30CA016672)
This publication has 47 references indexed in Scilit:
- Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 MutationJournal of Clinical Oncology, 2015
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 studyThe Lancet Oncology, 2014
- Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumoursBritish Journal of Cancer, 2014
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialThe Lancet Oncology, 2014
- Predictive biomarkers for cancer therapy with PARP inhibitorsOncogene, 2013
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trialThe Lancet Oncology, 2013
- Trapping of PARP1 and PARP2 by Clinical PARP InhibitorsCancer Research, 2012
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerNew England Journal of Medicine, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- DNA double-strand break repair by homologous recombinationMutation Research - Reviews in Mutation Research, 2004